Cargando…

Pulmonary Metastases After Low-Dose-Rate Brachytherapy for Localized Prostate Cancer

PURPOSE: To analyze unusual events and focus discussion on pulmonary metastasis in particular after low-dose-rate brachytherapy (LDR-BT) for prostate cancer (PCa). MATERIALS AND METHODS: A total of 616 consecutive patients who had undergone LDR-BT for clinically localized PCa at Jikei University Hos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kido, Masahito, Kuruma, Hidetoshi, Sasaki, Hiroshi, Miki, Kenta, Aoki, Manabu, Kimura, Takahiro, Takahash, Hiroyuki, Kanehira, Chihiro, Egawa, Shin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Urological Association 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4026656/ https://www.ncbi.nlm.nih.gov/pubmed/24868334 http://dx.doi.org/10.4111/kju.2014.55.5.309

Ejemplares similares

Do androgen deprivation and the biologically equivalent dose matter in low‐dose‐rate brachytherapy for intermediate‐risk prostate cancer?
por: Tabata, Ryuji, et al.
Publicado: (2016)

Analysis of prognostic factors in localized high-risk prostate cancer patients treated with HDR brachytherapy, hypofractionated 3D-CRT and neoadjuvant/adjuvant androgen deprivation therapy (trimodality therapy)
por: Aoki, Manabu, et al.
Publicado: (2014)

A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer
por: Miki, Kenta, et al.
Publicado: (2016)

Transperineal prostate brachytherapy, using I-125 seed with or without adjuvant androgen deprivation, in patients with intermediate-risk prostate cancer: study protocol for a phase III, multicenter, randomized, controlled trial
por: Miki, Kenta, et al.
Publicado: (2010)

Trimodal therapy with high-dose-rate brachytherapy and hypofractionated external beam radiation combined with long-term androgen deprivation for unfavorable-risk prostate cancer
por: Mori, Keiichiro, et al.
Publicado: (2021)

Prognostic Significance of Prostate-Specific Antigen Persistence after Radical Prostatectomy: A Systematic Review and Meta-Analysis
por: Kimura, Shoji, et al.
Publicado: (2021)

Clinical Efficacy and Openness to New Challenges of Low Dose Rate Brachytherapy for Prostate Cancer
por: Kato, Manabu, et al.
Publicado: (2023)

Low dose rate prostate brachytherapy
por: Stish, Bradley J., et al.
Publicado: (2018)

Global Trends of Latent Prostate Cancer in Autopsy Studies
por: Kimura, Takahiro, et al.
Publicado: (2021)

Interstitial High-Dose-Rate Brachytherapy of Liver Metastases in Oligometastatic Patients
por: Walter, Franziska, et al.
Publicado: (2021)

Intravitreal bevacizumab for delayed radiation maculopathy and papillopathy after irradiation for maxillary sinus cancer
por: Gondo, Miki, et al.
Publicado: (2011)

High dose-rate brachytherapy in the treatment of prostate cancer
por: Mendez, Lucas C., et al.
Publicado: (2018)

Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer
por: Tsuzuki, Shunsuke, et al.
Publicado: (2021)

Focal low-dose rate brachytherapy for the treatment of prostate cancer
por: Tong, William Y, et al.
Publicado: (2013)

Combined Interstitial and Intracavitary High-Dose Rate Brachytherapy of Cervical Cancer
por: Itami, Jun, et al.
Publicado: (2022)

Excessive waitlists and delays to treatment with low-dose-rate brachytherapy predict an increased risk of recurrence and metastases in intermediate-risk prostatic carcinoma
por: Khanolkar, Rutvij A., et al.
Publicado: (2021)

High-dose-rate interstitial brachytherapy for liver metastases: first study from India
por: Sharma, Daya Nand, et al.
Publicado: (2013)

Transition zone prostate cancer is associated with better clinical outcomes than peripheral zone cancer
por: Sato, Shun, et al.
Publicado: (2020)

Focal low-dose-rate prostate brachytherapy for low- and intermediate-risk prostate cancer
por: Kunogi, Hiroaki, et al.
Publicado: (2020)

Chronological Changes of Lower Urinary Tract Symptoms in Elderly Patients with Prostate Cancer after Low-Dose-Rate Prostate Brachytherapy
por: Tsuchiya, Kunihiro, et al.
Publicado: (2023)

High-dose-rate brachytherapy boost for prostate cancer: rationale and technique
por: Morton, Gerard C.
Publicado: (2014)

A novel perineal shield for low-dose-rate prostate brachytherapy
por: Weiner, Joseph P., et al.
Publicado: (2015)

Second salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer
por: Maenhout, Metha, et al.
Publicado: (2017)

Focal partial salvage low-dose-rate brachytherapy for local recurrent prostate cancer after permanent prostate brachytherapy with a review of the literature
por: Kunogi, Hiroaki, et al.
Publicado: (2016)

Ischemic proctitis after low‐dose‐rate brachytherapy using hydrogel spacer for prostate cancer
por: Toriumi, Ren, et al.
Publicado: (2022)

After low and high dose-rate interstitial brachytherapy followed by IMRT radiotherapy for intermediate and high risk prostate cancer
por: Nakamura, Satoshi, et al.
Publicado: (2016)

The highest percentage of Gleason Pattern 4 is a predictor in intermediate‐risk prostate cancer
por: Sato, Shun, et al.
Publicado: (2022)

Results of a Prospective Dose Escalation Study of Linear Accelerator–Based Virtual Brachytherapy (BOOSTER) for Prostate Cancer; Virtual HDR Brachytherapy for Prostate Cancer
por: Eade, Thomas, et al.
Publicado: (2019)

Direct Comparison of Two Different Definitions with Biochemical Recurrence after Low-Dose-Rate Brachytherapy for Prostate Cancer
por: Takeuchi, Shinichi, et al.
Publicado: (2023)

Low-dose-rate or high-dose-rate brachytherapy in treatment of prostate cancer – between options
por: Skowronek, Janusz
Publicado: (2013)

Treatment patterns of high-dose-rate and low-dose-rate brachytherapy as monotherapy for prostate cancer
por: Barnes, Justin, et al.
Publicado: (2019)

Unexpected lower biochemical control of high-dose-rate brachytherapy boost than low-dose-rate brachytherapy boost for clinically localized prostate cancer
por: Yamazaki, Hideya, et al.
Publicado: (2020)

A Phase 2 Randomized Pilot Study Comparing High-Dose-Rate Brachytherapy and Low-Dose-Rate Brachytherapy as Monotherapy in Localized Prostate Cancer
por: Hathout, Lara, et al.
Publicado: (2019)

Tri-Modality therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer (TRIP): study protocol for a phase III, multicenter, randomized, controlled trial
por: Konaka, Hiroyuki, et al.
Publicado: (2012)

The emerging role of high-dose-rate (HDR) brachytherapy as monotherapy for prostate cancer
por: Yoshioka, Yasuo, et al.
Publicado: (2013)

High-dose-rate brachytherapy as monotherapy for prostate cancer: technique, rationale and perspective
por: Yoshioka, Yasuo, et al.
Publicado: (2014)

Quality of life after high-dose-rate brachytherapy monotherapy for prostate cancer
por: Contreras, Jessika A., et al.
Publicado: (2015)

Bi‐objective optimization of catheter positions for high‐dose‐rate prostate brachytherapy
por: van der Meer, Marjolein C., et al.
Publicado: (2020)

Advantages of TRUS-based delineation for high-dose-rate prostate brachytherapy planning
por: Lavoie-Gagnon, Heloise, et al.
Publicado: (2022)

Control charts for evaluation of quality of low-dose-rate brachytherapy for prostate cancer
por: Nasser, Nicola J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fg33lcq8kt34c9lhmfkgutv9m4